Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 1.30% | |
| Wide Bands | Range Expansion | 1.30% | |
| Oversold Stochastic | Weakness | 1.30% | |
| NR7 | Range Contraction | -0.95% | |
| Wide Bands | Range Expansion | -0.95% | |
| Oversold Stochastic | Weakness | -0.95% | |
| Wide Bands | Range Expansion | -4.87% | |
| Oversold Stochastic | Weakness | -4.87% | |
| Pocket Pivot | Bullish Swing Setup | -1.50% | |
| Outside Day | Range Expansion | -1.50% |
| Alert | Time |
|---|---|
| Gap Up Partially Closed | about 1 hour ago |
| Gapped Up (Partial) | about 2 hours ago |
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 05/22/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.44 |
| 52 Week Low | 7.58 |
| Average Volume | 59,390 |
| 200-Day Moving Average | 11.04 |
| 50-Day Moving Average | 15.31 |
| 20-Day Moving Average | 15.38 |
| 10-Day Moving Average | 13.31 |
| Average True Range | 1.34 |
| RSI (14) | 34.64 |
| ADX | 34.81 |
| +DI | 10.75 |
| -DI | 28.30 |
| Chandelier Exit (Long, 3 ATRs) | 17.41 |
| Chandelier Exit (Short, 3 ATRs) | 15.40 |
| Upper Bollinger Bands | 20.11 |
| Lower Bollinger Band | 10.65 |
| Percent B (%b) | 0.18 |
| BandWidth | 61.55 |
| MACD Line | -1.06 |
| MACD Signal Line | -0.59 |
| MACD Histogram | -0.4702 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.75 | ||||
| Resistance 3 (R3) | 13.79 | 13.36 | 13.52 | ||
| Resistance 2 (R2) | 13.36 | 13.00 | 13.34 | 13.44 | |
| Resistance 1 (R1) | 12.85 | 12.78 | 12.64 | 12.81 | 13.36 |
| Pivot Point | 12.42 | 12.42 | 12.31 | 12.40 | 12.42 |
| Support 1 (S1) | 11.91 | 12.06 | 11.70 | 11.87 | 11.32 |
| Support 2 (S2) | 11.48 | 11.84 | 11.46 | 11.24 | |
| Support 3 (S3) | 10.97 | 11.48 | 11.17 | ||
| Support 4 (S4) | 10.93 |
